tDCS & Auditory Hallucinations in Schizophrenia

Herzog Hospital

Status

Terminated

Conditions

Schizophrenia

Treatments

Device: Active tDCS

Device: control

Study type

Interventional

Funder types

Other

Identifiers

NCT02227563

Meiron 2013-3

Details and patient eligibility

About

The aim of this study is to evaluate tDCS effects on schizophrenia symptoms, particularly on auditory verbal hallucinations. tDCS applied with cathodal (inhibitory) electrode over the left temporal parietal junction and anodal (excitatory) electrode over the left dorsolateral prefrontal cortex.

Enrollment

3 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Ages 18-60
Primary diagnosis of Diagnostic and Statistical Manual, fifth edition, schizophrenia
Persistent auditory verbal hallucinations
Right handed
Under stable doses of antipsychotic medication for ≥4 weeks
Normal hearing by self-report and physical exam
Use of effective method of birth control for women of childbearing capacity
Capable to provide informed consent. For patients judged to be incapable to provide informed consent the legal guardian of the patient must agree to participation in the study and provide signed informed consent

Exclusion criteria

Current or past history of substance dependence or abuse (excluding nicotine)
Other current Axis I disorders
History of seizure, epilepsy in self or first degree relatives, stoke, brain surgery, head injury, intracranial metal implants, known structural brain lesion, devices that may be affected by tDCS (pacemaker, medication pump, cochlear implant, implanted brain stimulator)
Frequent and persistent migraines
History of adverse reaction to neurostimulation
Participation in study of investigational medication within 6 weeks
Pregnancy
Women who are breast-feeding
Current significant laboratory abnormality